TWi Loses Patent Case Over Generic Oxtellar XR Seizure Drug

TWi Pharmaceuticals Inc.'s proposed generic version of epilepsy drug Oxtellar XR infringes patents belonging to Supernus Pharmaceuticals Inc., a federal appeals court said.

The U.S. Court of Appeals for the Federal Circuit, in a Sept. 6 nonprecedential decision, said it affirmed a district court ruling in Supernus’s favor because it properly relied on certain evidence from a related case.

The decision is a setback for TWi’s plans to release its extended-release oxcarbazepine tablets used to treat partial epileptic seizures.

Supernus sued TWi for allegedly infringing its patents covering Oxtellar XR—U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930—after TWi ...